<DOC>
	<DOC>NCT00615615</DOC>
	<brief_summary>Double-blind, randomized, placebo-controlled, multi-center clinical trial conducted to evaluate levetiracetam as adjunctive therapy in children (4-16 years) with refractory partial onset seizures.</brief_summary>
	<brief_title>Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>diagnosis of epilepsy with uncontrolled partial onset seizures, whether or not secondarily generalized, and the diagnosis was &gt;= 6 months before the Selection Visit; epilepsy was classifiable according to the ILAE Classification; &gt;= 4 partial onset seizures during the 4 weeks preceding the Selection Visit and were required to have &gt;= 4 partial onset seizures during each 4week interval of the Baseline Period to qualify for randomization; unsatisfactory current AED treatment in terms of efficacy and/or safety; stable AED treatment consisting of no more than two AEDs. treatable seizure etiology; epilepsy secondary to a progressive cerebral disease or any other progressively neurodegenerative disease, including Rasmussen and LandauKleffner diseases; history of status epilepticus which required hospitalization during 3 months prior to the Selection Visit; history of or the presence of pseudo seizures; current diagnosis of LennoxGastaut syndrome.</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>